Zura Bio (ZURA)
NASDAQ:ZURA
Top Page
Zura Bio
(NASDAQ:ZURA)
Select Model
Select Model
Rating:51Neutral
Price Target:
$6.00
▲(6.19% Upside)
Action:ReiteratedDate:03/20/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and accelerating cash burn). Corporate events provide a meaningful offset via strengthened liquidity and extended runway tied to Phase 2 milestones, while technicals are mixed-to-stable and valuation is constrained by loss-making status and no dividend.
Positive Factors
Advanced bispecific pipeline
A differentiated dual-pathway bispecific (tibulizumab) with Phase 2 studies and slated readouts provides structural de-risking potential. Successful clinical data would materially strengthen the company’s long-term commercial prospects and redress the typical binary risk of single-pathway biologics.
Negative Factors
Pre-revenue, widening losses
The company remains pre-revenue with materially negative net income, meaning profitability is contingent on clinical success and eventual commercialization. This structural unprofitability elevates dilution risk and makes long-term shareholder value highly dependent on trial outcomes rather than operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Advanced bispecific pipeline
A differentiated dual-pathway bispecific (tibulizumab) with Phase 2 studies and slated readouts provides structural de-risking potential. Successful clinical data would materially strengthen the company’s long-term commercial prospects and redress the typical binary risk of single-pathway biologics.
Read all positive factors
Zura Bio (ZURA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$536.08M
Dividend YieldN/A
Average Volume (3M)553.24K
Price to Earnings (P/E)―
Beta (1Y)1.41
Revenue GrowthN/A
EPS Growth-19.69%
CountryUS
Employees30
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.49
Shares Outstanding94,880,710
10 Day Avg. Volume585,142
30 Day Avg. Volume553,235
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.86
Price to Sales (P/S)0.00
P/FCF Ratio-7.60
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.45K
Enterprise Value/Ebitda-3.50
Forecast
1Y Price Target
$17.75Price Target Upside214.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.81
Revenue Forecast (FY)N/A
Zura Bio Business Overview & Revenue Model
Company Description
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways;...
How the Company Makes Money
null...
Zura Bio Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
52
Neutral
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -49.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -75.25M | -55.18M | -62.64M | -27.16M | 8.42M |
| Net Income | -99.35M | -52.40M | -60.36M | -25.74M | 8.42M |
Balance Sheet | |||||
| Total Assets | 113.95M | 179.53M | 100.84M | 5.26M | 140.55M |
| Cash, Cash Equivalents and Short-Term Investments | 109.41M | 176.50M | 99.81M | 1.57M | 729.22K |
| Total Debt | 0.00 | 0.00 | 0.00 | 7.76M | 0.00 |
| Total Liabilities | 12.41M | 19.51M | 21.29M | 27.32M | 10.35M |
| Stockholders Equity | 101.54M | 146.81M | 59.33M | -32.06M | 130.20M |
Cash Flow | |||||
| Free Cash Flow | -64.93M | -28.15M | -23.05M | -13.20M | -1.10M |
| Operating Cash Flow | -64.81M | -28.08M | -15.05M | -1.20M | -1.10M |
| Investing Cash Flow | -113.00K | -5.08M | -8.00M | -12.00M | -139.38M |
| Financing Cash Flow | -2.16M | 109.84M | 121.29M | 14.77M | 141.21M |
Zura Bio Technical Analysis
Neutral
5.65
Price Trends
6.20
Negative
5.40
Positive
3.91
Positive
Market Momentum
-0.15
Positive
43.25
Neutral
14.28
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZURA, the sentiment is Neutral. The current price of 5.65 is below the 20-day moving average (MA) of 5.87, below the 50-day MA of 6.20, and above the 200-day MA of 3.91, indicating a neutral trend. The MACD of -0.15 indicates Positive momentum. The RSI at 43.25 is Neutral, neither overbought nor oversold. The STOCH value of 14.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ZURA.
Zura Bio Risk Analysis
Zura Bio disclosed 84 risk factors in its most recent earnings report. Zura Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zura Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $395.82M | 9.56 | 27.78% | ― | -12.96% | 56.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $536.08M | -2.69 | -83.86% | ― | ― | -19.69% | |
49 Neutral | $194.92M | -5.01 | -99.45% | ― | -11.99% | -42.04% | |
47 Neutral | $755.67M | 0.02 | 72.70% | ― | ― | -1072.48% | |
45 Neutral | $270.40M | -4.62 | -69.63% | ― | 158.54% | 66.90% |
* Healthcare Sector Average
ZURA
Zura Bio
5.65
4.53
404.46%
PBYI
Puma Biotechnology
7.78
4.85
165.53%
PRQR
ProQR
1.85
0.67
56.78%
CLLS
Cellectis SA
3.59
2.09
139.33%
VOR
Vor Biopharma
15.47
1.65
11.94%
Zura Bio Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Zura Bio Reports 2025 Results, Extends Cash Runway Outlook
Positive
Mar 19, 2026
On March 19, 2026, Zura Bio reported its full-year 2025 results, highlighting progress in two ongoing Phase 2 trials of tibulizumab in hidradenitis suppurativa and systemic sclerosis, with HS topline data expected in late 2026 and SSc data in the ...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Zura Bio Updates Corporate Outlook on Lead Tibulizumab Program
Positive
Mar 10, 2026
On March 10, 2026, Zura Bio Ltd., a clinical-stage biotechnology company developing therapies for complex immune disorders, released an updated corporate presentation highlighting its lead asset tibulizumab, a first-in-class bispecific antibody in...
Business Operations and StrategyProduct-Related Announcements
Zura Bio Highlights TibuSURE Phase 2 Trial Design
Positive
Mar 5, 2026
On March 5, 2026, Zura Bio announced that the design of its ongoing global Phase 2 TibuSURE trial of tibulizumab (ZB-106) in diffuse cutaneous systemic sclerosis was accepted for poster presentation at the 9th Systemic Sclerosis World Congress in ...
Business Operations and StrategyPrivate Placements and Financing
Zura Bio Raises Capital Through Expanded Equity Offering
Positive
Feb 26, 2026
On February 24, 2026, Zura Bio entered into an underwriting agreement to sell 18.2 million Class A ordinary shares and 1.8 million pre-funded warrants at a public price of $6.25 per share, with the warrants priced at $6.249. The offer was conducte...
Business Operations and StrategyExecutive/Board Changes
Zura Bio Strengthens Board with Immunology and R&D Leaders
Positive
Feb 23, 2026
On February 21, 2026, Zura Bio reshaped its board, with longtime director Neil Graham resigning and seasoned immunology and drug development executives Mark Eisner and Ajay Nirula joining as new directors. The appointments, confirmed in a February...
Business Operations and StrategyProduct-Related Announcements
Zura Bio Advances Tibulizumab Strategy in Autoimmune Diseases
Positive
Feb 11, 2026
On Feb. 11, 2026, Zura Bio released an updated corporate presentation outlining its strategy to advance tibulizumab, a bispecific antibody designed to inhibit both IL-17 and BAFF, as a novel treatment for complex autoimmune diseases. The company h...
Business Operations and StrategyFinancial Disclosures
Zura Bio Updates Outlook and Clinical Development Plans
Positive
Jan 12, 2026
On January 12, 2026, Zura Bio Limited released an updated corporate presentation and a press release detailing corporate and clinical trial developments, including its outlook for 2026. The company highlighted ongoing Phase 2 studies of its lead d...
Business Operations and StrategyRegulatory Filings and Compliance
Zura Bio resets key agreements after internal review
Positive
Jan 2, 2026
On December 29, 2025, Zura Bio Limited entered into a new Letter Agreement with Athanor Capital and, on the same date, executed settlement and release agreements with Stone Peach and BAFFX17, terminating all outstanding agreements with those parti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.